Dietary methyl-consuming compounds and metabolic syndrome

Hypertension Research

Volumn 34, Issue 12, 2011, Pages 1239-1245

  Zhou, Shi Sheng ^a   Zhou, Yi Ming ^b   Li, Da ^a   Lun, Yong Zhi ^a  

^a DALIAN UNIVERSITY   (China)

^b OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

cardiovascular disease; diet; metabolic syndrome; methyl consuming compounds; niacin

Indexed keywords

ARSENIC; CATECHOLAMINE; FOLIC ACID; HOMOCYSTEINE METHYLTRANSFERASE; NICOTINIC ACID;

CARDIOVASCULAR DISEASE; DIETARY INTAKE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

ANIMALS; ARSENICALS; CATECHOLAMINES; DIET; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METHIONINE; NIACIN; REACTIVE OXYGEN SPECIES;

EID: 82955201840     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.133     Document Type: Review

References (88)

1. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009; 84: 705-712.
2. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 2005; 54: 1899-1906. (Pubitemid 40911250)
3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-1727.
4. The US Centers for Disease Control and Prevention's National Center for Health Statistics Prevalence of Obesity Among Children and Adolescents: United States, Trends 1963-1965 Through 2007-2008 http://www.cdc.gov/nchs/data/hestat/ obesity-child-07-08/obesity-child-07-08.htm.Last accessed on 19 April 2011.
5. The US Centers for Disease Control and Prevention's National Center for Health Statistics Crude and Age-Adjusted Percentage of Civilian, Noninstitutionalized Population with Diagnosed Diabetes, United States, 1980-2008 http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm. Last accessed on 19 April 2011.
6. Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: influence of geneenvironment interaction. Mutat Res 2009; 667: 35-43.
7. Konstantinova SV, Tell GS, Vollset SE, Nyga°rd O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 2008; 138: 914-920. (Pubitemid 351571592)
8. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389. (Pubitemid 26191904)
9. Dominguez LJ, Galioto A, Pineo A, Ferlisi A, Ciaccio M, Putignano E, Belvedere M, Costanza G, Barbagallo M. Age, homocysteine, and oxidative stress: relation to hypertension and type 2 diabetes mellitus. J Am Coll Nutr 2010; 29: 1-6.
10. González R, Pedro T, Real JT, Mart́nez-Hervás S, Abellán MR, Lorente R, Priego A, Catalá M, Chaves FJ, Ascaso JF, Carmena R. Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 115-120.
11. Becker A, Smulders YM, van Guldener C, Stehouwer CD. Epidemiology of homocysteine as a risk factor in diabetes. Metab Syndr Relat Disord 2003; 1: 105-120.
12. Hsieh MJ, Chen CC, Lee TH, Lee CH, Wen MS, Lin FC, Hsieh IC, Wu D. Metabolic syndrome and homocysteine level as predictors of the severity of coronary artery disease in patients with carotid stenosis. Am J Med Sci 2009; 338: 447-452.
13. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, Wollheim CB, Nitert MD, Ling C. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia 2011; 54: 360-367.
14. Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor ã coactivator 1á promoter. Hepatology 2010; 52: 1992-2000.
15. Gemma C, Sookoian S, Dieuzeide G, Garća SI, Gianotti TF, Gonzá lez CD, Pirola CJ. Methylation of TFAM gene promoter in peripheral white blood cells is associated with insulin resistance in adolescents. Mol Genet Metab 2010; 100: 83-87.
16. Clarke S, Banfield K. S-Adenosylmethionine-dependent methyltransferases. In Carmel R, Jacobsen DW (eds), Homocysteine in Health and Disease. Cambridge University Press: Cambridge, 2001, pp 63-78.
17. Craig SA. Betaine in human nutrition. Am J Clin Nutr 2004; 80: 539-549. (Pubitemid 41115516)
18. Ueland PM, Holm PI, Hustad S. Betaine: a key modulator of one-carbon metabolism and homocysteine status. Clin Chem Lab Med 2005; 43: 1069-1075. (Pubitemid 41581963)
19. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993; 7: 1344-1353. (Pubitemid 23336162)
20. Bailey LB, Moyers S, Gregory III JF. Folate. In Bowman BA, Russell RM (eds) Present Knowledge in Nutrition, 8th edn. International Life Sciences Institute Press: Washington, DC, 2001, pp 214-229.
21. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150.
22. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of homocysteinelowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009; 58: 1921-1928.
23. Ebbing M, Ueland PM. Prevention: B vitamins and CVD-failure to find a simple solution. Nat Rev Cardiol 2010; 7: 608-609.
24. Miller 3rd ER, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Metaanalysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 2010; 106: 517-527.
25. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest Jr J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
26. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26: 263-279.
27. Jacobsen DW. Biochemistry and metabolism. In Robinson K (ed) Homocysteine and Vascular Disease. Kluwer: Dordrecht, 2000, pp 15-35.
28. Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36: 19-24.
29. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005; 5: 124-139. (Pubitemid 40944288)
30. McCarty MF. Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. Med Hypotheses 2000; 55: 189-194.
31. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64. (Pubitemid 36078109)
32. Hall MN, Liu X, Slavkovich V, Ilievski V, Pilsner JR, Alam S, Factor-Litvak P, Graziano JH, Gamble MV. Folate, cobalamin, cysteine, homocysteine, and arsenic metabolism among children in Bangladesh. Environ Health Perspect 2009; 117: 825-831.
33. Appel LJ, Miller 3rd ER, Jee SH, Stolzenberg-Solomon R, Lin PH, Erlinger T, Nadeau MR, Selhub J. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000; 102: 852-857.
34. Zhou SS, Li D, Zhou YM, Sun WP, Liu QG. B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. BMC Public Health 2010; 10: 746.
35. Li D, Sun WP, Zhou YM, Liu QG, Zhou SS, Luo N, Bian FN, Zhao ZG, Guo M. Chronic niacin overload may be involved in the increased prevalence of obesity in US children. World J Gastroenterol 2010; 16: 2378-2387.
36. Nabipour I, Ebrahimi A, Jafari SM, Vahdat K, Assadi M, Movahed A, Moradhaseli F, Obeidi N, Sanjdideh Z. The metabolic syndrome is not associated with homocysteinemia: the Persian Gulf Healthy Heart Study. J Endocrinol Invest 2009; 32: 406-410.
37. Budak N, Yazici C, Oztü rk A, Bayram F, Mazicioqlu MM, Kurtoglu S. Is plasma homocysteine level associated with metabolic syndrome components in adolescents? Metab Syndr Relat Disord 2009; 7: 357-362.
38. Strassburg A, Krems C, Lührmann PM, Hartmann B, Neuhäuser- Berthold M. Effect of age on plasma homocysteine concentrations in young and elderly subjects considering serum vitamin concentrations and different lifestyle factors. Int J VitamNutr Res 2004; 74: 129-136. (Pubitemid 38788779)
39. Powers RW, Majors AK, Lykins DL, Sims CJ, Lain KY, Roberts JM. Plasma homocysteine and malondialdehyde are correlated in an age-and gender-specific manner. Metabolism 2002; 51: 1433-1438.
40. Hughes MF. Arsenic methylation, oxidative stress and cancer-is there a link? J Natl Cancer Inst 2009; 101: 1660-1661.
41. Druwe IL, Vaillancourt RR. Influence of arsenate and arsenite on signal transduction pathways: an update. Arch Toxicol 2010; 84: 585-596.
42. De Vizcaya-Ruiz A, Barbier O, Ruiz-Ramos R, Cebrian ME. Biomarkers of oxidative stress and damage in human populations exposed to arsenic. Mutat Res 2009; 674: 85-92.
43. Chen CJ, Wang SL, Chiou JM, Tseng CH, Chiou HY, Hsueh YM, Chen SY, Wu MM, Lai MS. Arsenic and diabetes and hypertension in human populations: a review. Toxicol Appl Pharmacol 2007; 222: 298-304.
44. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res 2006; 99: 692-705. (Pubitemid 44498303)
45. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 2011; 119: 11-19.
46. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press: Washington, DC, 1998, pp 123-149.
47. Menon RM, González MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 2007; 47: 681-688. (Pubitemid 46800415)
48. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43: 1337-1345.
49. Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab 2006; 91: 3303-3309. (Pubitemid 44402095)
50. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 1996; 45: 1631-1634. (Pubitemid 26357559)
51. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky Jr GJ, Porte Jr D. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-568. (Pubitemid 19125603)
52. Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101: 3B-8B.
53. Ginsberg HN. Niacin in the metabolic syndrome: more risk than benefit? Nat Clin Pract Endocrinol Metab 2006; 2: 300-301. (Pubitemid 43885891)
54. Kristensen T, Olcott EW. Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. J Comput Assist Tomogr 1999; 23: 314-317. (Pubitemid 29138514)
55. Rikans LL, Arata D, Cederquist DC. Fatty livers produced in albino rats by excess niacin in high fat diets. II. Effect of choline supplements. J Nutr 1965; 85: 107-112.
56. Mookerjea S, Park CE, Kuksis A. Lipid profiles of plasma lipoproteins of fasted and fed normal and choline-deficient rats. Lipids 1975; 10: 374-382.
57. Garrow TA. Choline and carnitine. In Bowman BA, Russel RM (eds) Present Knowledge in Nutrition, 8th edn International Life Sciences Institute Press, Washington, DC, 2001, pp 261-272.
58. Mansbach II CM. The origin of chylomicron phosphatidylcholine in the rat. J Clin Invest 1977; 60: 411-420. (Pubitemid 8154148)
59. Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 2009; 15: 3-11.
60. Zhou SS, Li D, Sun WP, Guo M, Lun YZ, Zhou YM, Xiao FC, Jing LX, Sun SX, Zhang LB, Luo N, Bian FN, Zou W, Dong LB, Zhao ZG, Li SF, Gong XJ, Yu ZG, Sun CB, Zheng CL, Jiang DJ, Li ZN. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 2009; 15: 5674-5684.
61. Hoshino J, Schlü ter U, Kröger H. Nicotinamide methylation and its relation to NAD synthesis in rat liver tissue culture. Biochemical basis for the physiological activities of 1-methylnicotinamide. Biochim Biophys Acta 1984; 801: 250-258. (Pubitemid 14007748)
62. Shibata K, Shimada H, Taguchi H. Fate of nicotinamide differs due to an intake of nicotinamide. Biosci Biotechnol Biochem 1996; 60: 1204-1206. (Pubitemid 26368666)
63. Kang-Lee YA, McKee RW, Wright SM, Swendseid ME, Jenden DJ, Jope RS. Metabolic effects of nicotinamide administration in rats. J Nutr 1983; 113: 215-221. (Pubitemid 13111832)
64. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities Study. Circulation 2008; 117: 754-761. (Pubitemid 351640676)
65. Fung TT, Schulze M, Manson JE, Willett WC, Hu FB. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med 2004; 164: 2235-2240. (Pubitemid 39452984)
66. Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 2009; 89: 535-606.
67. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5: 86-99. (Pubitemid 13179794)
68. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18: 655-673. (Pubitemid 30406736)
69. Behonick GS, Novak MJ, Nealley EW, Baskin SI. Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J Appl Toxicol 2001; 21(Suppl 1): S15-S22.
70. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007; 59: 125-150. (Pubitemid 46855437)
71. Mizukoshi M, Hano T, Kuchii M, Nishio I, Masuyama Y. Plasma noradrenaline and its deaminated metabolites in essential hypertension and pheochromocytoma. Jpn Circ J 1985; 49: 1035-1042. (Pubitemid 16219095)
72. Ludwig J, Gerlich M, Halbrügge T, Graefe KH. Plasma norepinephrine and dihydroxyphenylglycol in essential hypertension. Hypertension 1991; 17: 546-552.
73. Ferrier C, Esler MD, Eisenhofer G, Wallin BG, Horne M, Cox HS, Lambert G, Jennings GL. Increased norepinephrine spillover into the jugular veins in essential hypertension. Hypertension 1992; 19: 62-69.
74. Vahteristo L, Lehikoinen K, Ollilainen V, Varo P. Application of an HPLC assay for the determination of folate derivatives in some vegetables, fruits, and berries consumed in Finland. Food Chem 1997; 59: 589-597. (Pubitemid 27197130)
75. Caudill MA, Cruz AC, Gregory 3rd JF, Hutson AD, Bailey LB. Folate status response to controlled folate intake in pregnant women. J Nutr 1997; 127: 2363-2370.
76. Green TJ, Skeaff CM, McMahon JA, Venn BJ, Williams SM, Devlin AM, Innis SM. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. Br J Nutr 2010; 103: 1629-1634.
77. Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr 2003; 133: 1302-1307. (Pubitemid 36548698)
78. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-518.
79. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res 2002; 52: 1-23. (Pubitemid 34130239)
80. Svensson CK. Biotransformation of drugs in human skin. Drug Metab Dispos 2009; 37: 247-253.
81. Sato K. The physiology, pharmacology, and biochemistry of the eccrine sweat gland. Rev Physiol Biochem Pharmacol 1977; 79: 51-131.
82. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992; 268: 63-67.
83. Ford ES, Li C, Zhao G, Pearson WS, Tsai J, Churilla JR. Sedentary behavior, physical activity, and concentrations of insulin among US adults. Metabolism 2010; 59: 1268-1275.
84. Borrione P, Pigozzi F, Massazza G, Schonhuber H, Viberti G, Paccotti P, Angeli A. Hyperhomocysteinemia in winter elite athletes: a longitudinal study. J Endocrinol Invest 2007; 30: 367-375. (Pubitemid 47098231)
85. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 2004; 160: 492-502. (Pubitemid 39166983)
86. Keatinge WR, Donaldson GC. Cardiovascular mortality in winter. Arctic Med Res 1995; 54(Suppl 2): 16-18.
87. Gauglitz GG, Herndon DN, Kulp GA, Meyer 3rd WJ, Jeschke MG. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab 2009; 94: 1656-1664.
88. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18: 297-304.